Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

, MRK

Merck

$54.90

(0.00%)

07:33
02/15/18
02/15
07:33
02/15/18
07:33

Bristol-Myers upgraded on immuno-oncology growth prospects at Morgan Stanley

As previously reported, Morgan Stanley analyst David Risinger upgraded Bristol-Myers (BMY) to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. After the analyst reviewed combo toxicity in select combo studies with similar dosing as Bristol's CM-227 and compared cross trial against Merck's (MRK) Keynote-021G trial that tested Keytruda + chemo, he concluded that discontinuation rates due to side effects appear roughly comparable and now thinks Opdivo + Yervoy toxicity in lung cancer is likely to be acceptable. Risinger raised his price target on Bristol-Myers shares to $78 from $63.

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

MRK

Merck

$54.90

(0.00%)

  • 15

    Feb

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

BMY Bristol-Myers
$65.35

1.48 (2.32%)

02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
MRK Merck
$54.90

(0.00%)

01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
02/14/18
BMOC
02/14/18
NO CHANGE
Target $65
BMOC
Outperform
Merck price target lowered to $65 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Merck to $65 after the company discontinued its APECS study. The analyst sees this as "another setback that increases Merck's dependence on Keytruda" and contends that the company needs other meaningful drivers. Arfaei keeps his Outperform rating based on his confidence in Keytruda growth and Merck's Immuno-oncology execution.
02/15/18
PIPR
02/15/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using the selloff yesterday in shares of Biogen (BIIB) as a buying opportunity. The stock pulled back after management disclosed at a conference plans to up-size the Phase 3 aducanumab program by 510 patients total. While "this is a bit unnerving," particularly on the heels of another Phase 3 Alzheimer's failure for Merck's (MRK) verubecestat, the study remains blinded and variability on the primary endpoint can stem from a host of reasons, not all of them bad, Raymond tells investors in a research note titled "Aducanumab P3 Upsizing Doesn't Tell Us Much." The analyst does not think yesterday's news says much about the chances for an interim analysis or about aducanumab's efficacy profile. He keeps an Overweight rating on Biogen with a $407 price target.

TODAY'S FREE FLY STORIES

BNFT

Benefitfocus

$49.88

-1.99 (-3.84%)

20:44
12/18/18
12/18
20:44
12/18/18
20:44
Hot Stocks
Benefitfocus sees FY19 revenue growth in 'mid-to-high teens' »

Sees FY19 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

AGCO

Agco

$56.59

2.7 (5.01%)

20:36
12/18/18
12/18
20:36
12/18/18
20:36
Earnings
Agco guides initial FY19 EPS ~$4.60, consensus $4.59 »

Sees FY19 revenue around…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

NVS

Novartis

$85.40

-0.4 (-0.47%)

20:28
12/18/18
12/18
20:28
12/18/18
20:28
Hot Stocks
Novartis announces licensing of pradigastat to Anji Pharmaceuticals »

Anji Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

SQ

Square

$59.91

1.28 (2.18%)

20:25
12/18/18
12/18
20:25
12/18/18
20:25
Recommendations
Square analyst commentary at Tigress Financial »

Square offers continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

PAYX

Paychex

$64.32

-0.63 (-0.97%)

, GIS

General Mills

$36.70

-0.03 (-0.08%)

20:25
12/18/18
12/18
20:25
12/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PAYX

Paychex

$64.32

-0.63 (-0.97%)

GIS

General Mills

$36.70

-0.03 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 19

    Dec

FSNUY

Fresenius SE

$0.00

(0.00%)

20:21
12/18/18
12/18
20:21
12/18/18
20:21
Upgrade
Fresenius SE rating change at Goldman Sachs »

Fresenius SE upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNFT

Benefitfocus

$49.88

-1.99 (-3.84%)

20:19
12/18/18
12/18
20:19
12/18/18
20:19
Recommendations
Benefitfocus analyst commentary at Jefferies »

Benefitfocus analyst day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FN

Fabrinet

$51.13

2.17 (4.43%)

20:06
12/18/18
12/18
20:06
12/18/18
20:06
Recommendations
Fabrinet analyst commentary at Piper Jaffray »

Fabrinet among the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEE

Sealed Air

$33.96

0.17 (0.50%)

19:38
12/18/18
12/18
19:38
12/18/18
19:38
Upgrade
Sealed Air rating change at BMO Capital »

Sealed Air upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$124.29

-0.2 (-0.16%)

19:31
12/18/18
12/18
19:31
12/18/18
19:31
Hot Stocks
Vice President of Caterpillar Excavation unit to step down »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$71.99

-2.01 (-2.72%)

19:10
12/18/18
12/18
19:10
12/18/18
19:10
Periodicals
Exxon tells EPA it opposes weakening Obama-era emissions rules, Reuters says »

Exxon Mobil issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

CBS

CBS

$46.21

-0.6 (-1.28%)

, DIS

Disney

$109.43

-1.2 (-1.08%)

19:07
12/18/18
12/18
19:07
12/18/18
19:07
Periodicals
CBS poised to ramp up CEO search after denying Moonves severance, Bloomberg says »

CBS's (CBS) board is…

CBS

CBS

$46.21

-0.6 (-1.28%)

DIS

Disney

$109.43

-1.2 (-1.08%)

FOX

21st Century Fox

$48.49

-0.29 (-0.59%)

FOXA

21st Century Fox

$48.78

-0.22 (-0.45%)

TRCO

Tribune Media

$45.25

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 05

    Feb

JBL

Jabil

$22.21

0.65 (3.01%)

, SCS

Steelcase

$14.19

0.02 (0.14%)

19:02
12/18/18
12/18
19:02
12/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Jabil…

JBL

Jabil

$22.21

0.65 (3.01%)

SCS

Steelcase

$14.19

0.02 (0.14%)

ADMS

Adamas Pharmaceuticals

$8.11

-0.67 (-7.63%)

ANGI

Angi Homeservices

$15.64

-0.01 (-0.06%)

MU

Micron

$34.12

0.23 (0.68%)

LRCX

Lam Research

$138.01

2.39 (1.76%)

AMAT

Applied Materials

$33.27

0.62 (1.90%)

FDX

FedEx

$185.01

2.81 (1.54%)

UPS

UPS

$97.25

0.33 (0.34%)

SURF

Surface Oncology

$7.35

-0.44 (-5.65%)

GSAT

Globalstar

$0.36

0.0082 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 18

    Dec

  • 19

    Dec

  • 08

    Jan

  • 19

    Dec

CBS

CBS

$46.21

-0.6 (-1.28%)

18:45
12/18/18
12/18
18:45
12/18/18
18:45
Periodicals
CBS poised to ramp up CEO search after denying Moonves severance, Bloomberg says »

CBS's board is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

AMTB

Mercantil Bank

$12.00

-0.3 (-2.44%)

18:41
12/18/18
12/18
18:41
12/18/18
18:41
Syndicate
Mercantil Bank 6.3M share IPO priced at $13.00 per share »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

QDEL

Quidel

$50.00

0.9 (1.83%)

18:39
12/18/18
12/18
18:39
12/18/18
18:39
Hot Stocks
Quidel receives CE Mark for Sofia 2 Lyme+ FIA for use with Sofia 2 instrument »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAOI

Applied Optoelectronics

$15.40

-1.73 (-10.10%)

, ACIA

Acacia Communications

$39.32

-0.53 (-1.33%)

18:34
12/18/18
12/18
18:34
12/18/18
18:34
Recommendations
Applied Optoelectronics, Acacia Communications, Cisco, Fabrinet, Finisar analyst commentary at Piper Jaffray »

Cisco's Luxtera deal…

AAOI

Applied Optoelectronics

$15.40

-1.73 (-10.10%)

ACIA

Acacia Communications

$39.32

-0.53 (-1.33%)

CSCO

Cisco

$44.05

-0.16 (-0.36%)

FN

Fabrinet

$51.13

2.17 (4.43%)

FNSR

Finisar

$21.57

0.005 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 04

    Mar

WGO

Winnebago

$19.96

-0.73 (-3.53%)

18:20
12/18/18
12/18
18:20
12/18/18
18:20
Hot Stocks
Winnebago to withdraw its Chicago Stock Exchange listing »

Winnebago Industrie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

CVS

CVS Health

$69.55

-1.12 (-1.58%)

, AET

Aetna

$0.00

(0.00%)

18:07
12/18/18
12/18
18:07
12/18/18
18:07
Periodicals
Judge weighs naming monitor to oversee CVS during court process, Reuters says »

Judge Richard Leon of the…

CVS

CVS Health

$69.55

-1.12 (-1.58%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FDX

FedEx

$185.01

2.81 (1.54%)

, AMZN

Amazon.com

$1,551.00

29.66 (1.95%)

18:05
12/18/18
12/18
18:05
12/18/18
18:05
Hot Stocks
FedEx sees no impact from Amazon's air freight ops »

FedEx (FDX) says it is…

FDX

FedEx

$185.01

2.81 (1.54%)

AMZN

Amazon.com

$1,551.00

29.66 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 19

    Dec

  • 20

    Dec

  • 04

    Jan

  • 07

    Jan

VZ

Verizon

$55.67

-0.29 (-0.52%)

18:04
12/18/18
12/18
18:04
12/18/18
18:04
Hot Stocks
Verizon Media Group will replace the Oath brand »

Oath COO Guru Gowrappan …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CE

Celanese

$85.39

0.98 (1.16%)

18:02
12/18/18
12/18
18:02
12/18/18
18:02
Hot Stocks
Celanese raises GUR and GHR grades engineered materials prices by 10% »

Celanese announced price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$185.01

2.81 (1.54%)

17:55
12/18/18
12/18
17:55
12/18/18
17:55
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says profit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FDX

FedEx

$185.01

2.81 (1.54%)

17:52
12/18/18
12/18
17:52
12/18/18
17:52
Hot Stocks
FedEx sees voluntary buyout saving company $225M-$275M in FY20 »

Sees 18-24 month payback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

VVV

Valvoline

$19.00

0.21 (1.12%)

17:51
12/18/18
12/18
17:51
12/18/18
17:51
Hot Stocks
Valvoline to open 17 acquired Quick-Lube centers in California »

Valvoline Inc. - a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.